Meaningful change in oncology quality-of-life instruments: A systematic literature review

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 4, 2012, Pages 475-483

  Bedard, Gillian ^a   Zeng, Liang ^a   Lam, Henry ^a   Cella, David ^b   Zhang, Liying ^a   Lauzon, Natalie ^a   Chow, Edward ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

meaningful change; oncology; quality of life

Indexed keywords

ANALYTICAL ERROR; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ASSESSMENT TOOL; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY - GENERAL; FUNCTIONAL STATUS; GLIOMA; HEALTH STATUS; HEALTH SURVEY; HUMAN; MEASUREMENT; ONCOLOGY; PATIENT ATTITUDE; POPULATION RESEARCH; QUALITY OF LIFE; QUALITY OF LIFE INSTRUMENT; QUESTIONNAIRE; RATING SCALE; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; WELLBEING;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84866675469     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.34     Document Type: Review

References (29)

1. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual. Life Res. 11(3), 207-221 (2002
2. Osoba D. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med. Care 40, III31-III38 (2002
3. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T; Clinical Significance Consensus Meeting Group. Estimating clinically significant differences in quality of life outcomes. Qual. Life Res. 14(2), 285-295 (2005
4. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual. Life Res. 2(3), 221-226 (1993
5. Marquis P, Chassany O, Abetz L. A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value Health 7(1), 93-104 (2004
6. Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J. Clin. Epidemiol. 57(9), 898-910 (2004
7. Maringwa JT, Quinten C, King M et al.; EORTC PROBE Project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support. Care Cancer 19(11), 1753-1760 (2011
8. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin. Proc. 77(4), 371-383 (2002
9. Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiol. 55(3), 285-295 (2002
10. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy - Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 12(1), 124-129 (2009
11. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating minimal important differences for the FACTMelanoma quality of life questionnaire. Value Health 12(8), 1144-1150 (2009
12. Eton DT, Cella D, Bacik J, Motzer RJ. A brief symptom index for advanced renal cell carcinoma. Health Qual. Life Outcomes 4, 68 (2006
13. Colwell HH, Mathias SD, Turner MP et al. Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): Reliability, validity, responsiveness, and clinical meaningfulness. Oncologist 15(3), 308-316 (2010
14. Eton DT, Cella D, Yount SE, Davis KM. Validation of the Functional Assessment of Cancer Therapy - Lung symptom index-12 (FLSI-12). Lung Cancer 57(3), 339-347 (2007
15. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual. Life Outcomes 5, 70 (2007
16. Maringwa J, Quinten C, King M et al.; EORTC PROBE Project and Brain Cancer Group. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann. Oncol. 22(9), 2107-2112 (2011
17. Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: A comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur. J. Haematol. 87(4), 330-337 (2011
18. Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy - Biologic Response Modifiers (FACTBRM) instrument. Value Health 8(2), 117-127 (2005
19. Ringash J, Bezjak A, O'Sullivan B, Redelmeier DA. Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients. Qual. Life Res. 13(4), 725-733 (2004
20. Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer 110(1), 196-202 (2007
21. Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann. Oncol. 17(2), 304-312 (2006
22. Cella D, Yount S, Du H et al. Development and validation of the Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI). J. Support. Oncol. 4(4), 191-199 (2006
23. No authors listed. Cancer pain relief and palliative care. Report of a WHO expert committee. World Health Organ. Tech. Rep. Ser. 804, 1-75 (1990
24. Funk GF, Karnell LH, Smith RB, Christensen AJ. Clinical significance of health status assessment measures in head and neck cancer: What do quality-of-life scores mean? Arch. Otolaryngol. Head Neck Surg. 130(7), 825-829 (2004
25. Lemieux J, Beaton DE, Hogg-Johnson S, Bordeleau LJ, Goodwin PJ. Three methods for minimally important difference: No relationship was found with the net proportion of patients improving. J. Clin. Epidemiol. 60(5), 448-455 (2007
26. Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur. J. Haematol. 84(4), 345-353 (2010
27. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol. 19(5), 1266-1274 (2001
28. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med. Care 41, 582-592 (2003
29. Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA; Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: A users' guide for clinicians. Mayo Clin. Proc. 77(6), 561-571 (2002